Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE: MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria
NCT06144840Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Dec 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of dersimelagon in erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), sponsored by Mitsubishi Tanabe Pharma Corporation. Started Dec 2023; status: completed.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NCT06144840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06144840.